Efficacy Of Intravenous Iron Sucrose Research Articles

(1368) - Safety and Efficacy of Intravenous Iron Sucrose in Children with Cardiac Disease

(1368) - Safety and Efficacy of Intravenous Iron Sucrose in Children with Cardiac Disease

Efficacy and safety of intravenous iron sucrose for treatment of iron deficiency anemia in pregnancy

<p class="abstract"><strong>Background: </strong>Leading cause of anemia is due to thedeficiency of iron in pregnant women. The aim of the study was to evaluate the efficacy of intravenous iron sucrose for the treatment of iron deficiency anemia in pregnancy particularly for those who had unsatisfactory response to oral iron therapy.</p><p class="abstract"><strong>Methods: </strong>This is an open label, observational study that was carried out in Jamal Noor Hospital, Karachi for 6 months by using non-probability consecutive sampling technique, after taking ethical approval. Seventy two pregnant women with level of Hb equivalent to or <10 g/dl, Serum ferritin level equivalent to or <10 μg/l with the age ranging from 18-40 years, Gestational age 16 weeks or above were included in the study. A two times-weekly dose of 200 mg of iron sucrose (Axifer) intravenously were infused to pregnant women. However, the dose was calculated for every patient through total iron deficit. SPSS version 22 was used to analyze the data.</p><p class="abstract"><strong>Results: </strong>The study results showed that the mean age of the pregnant womenwas 25.83±5.03 years, their mean weight was 59.50±10.28 kg, and their mean gestational week was 28.88±4.09. It showed that both the haemoglobin (9.01±0.74 mg/dl versus 11.92±11.07 mg/dl), (p<0.001) and ferritin levels (9.85±12.38 ng/ml versus 50.74±59.42 ng/ml), (p<0.001)were significantly increased at term after receiving intravenous iron sucrose as compared to the baseline.</p><p class="abstract"><strong>Conclusions:</strong> This study concluded that the administration of iron sucrose (Axifer) intravenously is a secure and effective choice in the management of iron deficiency anemia in pregnant women particularly for those who had inadequate response to oral iron supplementation.</p>

Addition of oral iron bisglycinate to intravenous iron sucrose for the treatment of postpartum anemia—randomized controlled trial

Studies that have compared the effectiveness of oral with intravenous iron supplements to treat postpartum anemia have shown mixed results. The superiority of one mode of treatment vs the other has yet to be demonstrated. Therefore, despite guidelines and standards of care, treatment approaches vary across practices. A single 500 mg dose of iron sucrose, which is higher than what is usually administered, has not been evaluated to treat postpartum moderate to severe anemia. This study aimed to compare the efficacy of intravenous iron sucrose alone with intravenous iron sucrose in combination with oral iron bisglycinate supplementation in treating moderate to severe postpartum anemia. A randomized controlled trial was conducted between February 2015 and June 2020. Women with postpartum hemoglobin level of ≤9.5 g/dL were treated with 500 mg intravenous iron sucrose after an anemia workup, which ruled out other causes for anemia. In addition to receiving intravenous iron, women were randomly allocated to receive either 60 mg of oral iron bisglycinate for 45 days or no further iron supplementation. The primary outcome was hemoglobin level at 6 weeks after delivery. Secondary outcomes were iron storage parameters and quality of life. Of 158 patients who participated, 63 women receiving intravenous and oral iron, and 44 women receiving intravenous iron-only, completed the study and were included in the analysis. Baseline and obstetrical characteristics were similar between the study cohorts. Although statistically significant, postpartum hemoglobin levels were only 0.4 g/dL higher in the intravenous and oral iron than intravenous iron-only cohort (12.4 g/dL vs 12.0 g/dL, respectively; P=.03), with a respective increase from baseline of 4.2 g/dL vs 3.7 g/dL (P=.03). There was no difference in the rate of women with hemoglobin level of <12.0 or 11.0 g/dL. Iron storage and health quality were not different between the cohorts. Oral iron treatment was associated with 29% rate of adverse effects. Compliance and satisfaction from treatment protocol were high in both cohorts. Intravenous 500 mg iron sucrose treatment alone is sufficient to treat postpartum anemia without the necessity of adding oral iron treatment.

A comparative randomized study to observe the effect of parentral iron sucrose and oral iron in the treatment of iron deficiency anaemia in pregnancy

Objective: Iron deficiency anaemia is a common problem in obstetrics throughout the developing World, despite the fact that this problem is largely preventable & easily treatable. The aim of this study was to compare the efficacy of intravenous iron sucrose versus oral iron in the treatment of iron deficiency anemia during pregnancy.Methods: 100 pregnant women with gestational age between 26 to 34 weeks with mild to moderate iron deficiency anemia (Hb 7-10 g/dl) were selected. The target Hb level was 11 g/dl. Selected patients were divided in two equal group, Group-A received IV iron sucrose. The drug was administered by IV infusion. The group B received ferrous sulphate as oral iron. Repeat laboratory estimations were done after six weeks. Data were analyzed using SYSTAT 7.0 (SPSS Inc. USA). Differences between mean percentages were analyzed by independent -‘t’ test.Results: Rise in haemoglobin concentration was observed from 8.41±0.13 to 11.63±0.14 g/dl in Group A and from 8.43±0.15 to 10.09±0.16 g/dl in group B after six weeks.Conclusion: The present study revealed that intravenous iron sucrose is a safe and effective alternative to oral iron in treatment of iron deficiency anaemia of pregnancy.

Comparative study of efficacy of intravenous iron sucrose versus ferric carboxymaltose in the treatment of iron deficiency anaemia

Background: Iron deficiency anaemia (IDA) is a common haematological complication with potentially serious clinical consequences that may require intravenous iron therapy. Parenteral iron therapy results faster and higher replenishment of iron stores and correction of Haemoglobin (Hb) levels with better compliance. The study was to compare the efficacy of intravenous ferric carboxymaltose with intravenous iron sucrose to treat iron deficiency anaemia. Methods: 188 patients were included in the study. 100 patients were given iron sucrose. After a 25 mg test dose on the first infusion only, this was given at a dose of 300 mg by intravenous infusion diluted in 100 ml of normal saline, every alternate day. 88 patients were treated with ferric carboxymaltose at a dose of 500 mg diluted in 100 ml of normal saline by intravenous infusion. Hb level and serum Ferritin of both groups were done before iron therapy and 3 weeks after iron therapy. Results: The mean±SD rise of haemoglobin concentration 3 weeks after iron therapy in iron sucrose group was 11.0±0.61 g/dL, while in ferric carboxymaltose group was 11.2±0.64 g/dL. The mean±SD ferritin 3 weeks after iron therapy in iron sucrose group was 76.0±14.28 ng/mL, while in ferric carboxymaltose group was 80.0±15.16 ng/mL. No serious adverse events were reported in either the ferric carboxymaltose group or iron sucrose group. Conclusions: Ferric carboxymaltose causes higher rise in Hb level as compared to parenteral iron sucrose.

Safety and Efficacy of Intravenous Iron Sucrose versus Low Molecular Weight Iron Dextran for Treatment of Iron Deficiency Anemia in Pregnancy: A Randomized Controlled Trial.

ObjectiveThis study aimed to compare the efficacy, side effects, and clinical outcomes between parenteral iron sucrose complex (ISC) and low-molecular-weight iron dextran (LMWID) for iron deficiency anemia (IDA) in pregnancy.MethodsThe study was conducted in a Malaysian tertiary hospital for a period of 1 year. Forty pregnant women with IDA between 24 and 38 weeks of gestation were randomized into two groups receiving treatment with either ISC or LMWID.ResultsNo significant difference was found between the groups in terms of demographic data, parity, and mean gestational age. A mean total of 835 ± 150 mg doses of ISC and 656 ± 382 mg doses of LMWID were administered (P = 0.0001). Adverse events were reported in five patients who received LMWID and none in those treated with ISC (P = 0.024). The mean hemoglobin (Hb) level increment 2 weeks post treatment was higher among those who received ISC than in those who received LMWID. The ISC group demonstrated an increase of 1.91 ± 1.10 g/dL (from 8.43 ± 1.03 g/dL to 10.29 ± 0.90 g/dL) compared with the LMWID group at 1.39 ± 0.54 g/dL (from 8.61 ± 0.70 g/dL to 9.92 ± 0.88 g/dL, P = 0.023). All participants in both groups delivered at term. The estimated blood loss during delivery was significantly higher in the LMWID group (359 ± 247 mL) than in the ISC group (280 ± 100 mL, P = 0.026). Otherwise, no significant difference was observed in terms of Hb level during delivery and the perinatal outcomes for both groups.ConclusionParenteral ISC is more effective than LMWID in treating maternal IDA, and it is associated with fewer adverse events.

A comparative study to evaluate oral iron and intravenous iron sucrose for treatment of anemia in pregnancy in a poor socioeconomic region of Northeast India.

Objective:The prevalence of anemia during pregnancy is as high as 80% in some sections of the Indian population. Iron therapy in different forms has been found to alleviate anemia and yield good fetomaternal outcome. This study aims to evaluate the efficacy of intravenous iron sucrose (IVIS) versus oral iron in treating anemia among the antenatal mothers attending a tertiary care center of Northeast India.Materials and Methods:One hundred women between 18 and 28 weeks of gestation with diagnosed iron-deficiency anemia and hemoglobin (Hb) of 7–10.9 g/dL were enrolled to be administered either oral ferrous sulfate 200 mg twice daily or requisite dose of IVIS 100 mg in 100 ml normal saline on alternate days. Hb and hematocrit were measured at the time of enrollment, 4th week, and 8th week of therapy. Acceptability of both the drugs based on like and dislike after interviewing the study participants was recorded. Adverse drug reactions, gestational age at delivery, and neonatal birth weight were also noted in both the groups. The results were analyzed by Student's t-test and Chi-square test.Results:Hb and hematocrit values were found to be increased in both the groups at 4th and 8th weeks. When both the groups were compared, the rise in the values was higher in the iron sucrose group (at 4th week P = 0.01 and at 8th week P = 0.00). The number of participants who reached target Hb levels at 4 weeks was 41 (82%) with oral iron and 48 (96%) with iron sucrose. In the iron sucrose group, no adverse effects were observed, suggesting its safety, and the acceptability and newborn birth weight were noted to be higher.Conclusion:IVIS was found to be more effective than oral iron therapy in treating antenatal anemia with no serious adverse drug reactions.

The Efficacy of Intravenous Iron Sucrose in Treating Iron Deficiency Anemia of Pregnancy [23D

INTRODUCTION: Women diagnosed with iron deficiency anemia (IDA) in pregnancy are routinely treated with oral iron supplements, although side effects often prompt non-adherence. Parenteral administration of iron sucrose is reported to be a useful tool in the management of IDA in pregnancy. Inadequate iron stores during the prenatal period is often managed with transfusion of packed red blood cells (PRBCs). We have previously reported in a small sample that antenatal use of iron sucrose was associated with lower rates of PRBCs transfused during pregnancy. Our aim was to evaluate iron sucrose as a tool to treat IDA during pregnancy. METHODS: Searched PubMed and Google scholar using terms: pregnancy, iron sucrose and anemia for articles published between January 2017 and August 2018. RESULTS: 813 RCTs and observational studies were identified. After applying exclusion criteria, 11 articles were selected for review. Between 14 and 36 weeks of gestation 2420 women between 14 and 36 weeks of gestation were studied. Antenatal infusion of parenteral iron sucrose was universally associated with increased concentration of hemoglobin and ferritin. While infusion site erythema was common, anaphylaxis was rare. CONCLUSION: Intravenous iron sucrose is an effective method of treating IDA in pregnant women with minimal side effects. These results, as well as our previous report associating intravenous iron sucrose with decreased PRBC transfusion, demonstrate the potential of this therapy to treat IDA and decrease rates of allogenic blood transfusion. We recommend additional studies be conducted to show the correlation between iron sucrose treatment and incidence of blood transfusion in pregnant women.

The role of intravenous iron sucrose treatment in patients with iron deficiency anemia in pregnancy: A prospective controlled cohort study

Aim: Iron deficiency anemia is the most common nutritional disorder in pregnancy and approximately 40% of all pregnant women are complicated with perinatal morbidity and mortality. In this work, the efficacy of intravenous iron sucrose and oral iron hydroxypolymaltose is compared in third-trimester pregnancies with iron deficiency anemia.Methods: A prospective cohort study is planned. A total of 140 pregnant women were enrolled in the study in two groups. The first group consisted of patients who could not tolerate oral iron therapy and were treated with intravenous iron sucrose and the second group was composed of patients who used oral iron III hydroxy polymaltose for anemia treatment in third trimester.. The treatment effects of blood count parameters were compared between groups.Results: Demographic and baseline characteristics were similar in both groups. Mean hemoglobin levels before treatment were 9.03±0.47 g/L in the intravenous treatment group and 8.82±0.39 g/L in the oral treatment group. 30 days after treatment, the mean hemoglobin levels were 10.7±0.55 g/L in the intravenous treatment group and 10.9±0.58 g/L in the oral treatment group. Before delivery, the mean hemoglobin levels were 11.38±0.56 g/L in the intravenous treatment group and 11.35±0.47 g/L in the oral treatment group. There was no significant difference between groups for hemoglobin levels before treatment, 30 days after treatment, and before delivery (p=0.355, p=0.513, and p=0.975, respectively). The mean mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) levels were not statistically different between groups before treatment, 30 days after treatment, and before delivery.Conclusions: Intravenous administration of iron sucrose is an alternative to blood transfusion for the treatment of pregnant women with iron deficiency anemia during the third trimester.

Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease.

Background. Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose. To assess safety and efficacy of intravenous iron sucrose (IVIS) in children with IBD. Methods. We reviewed medical records of IBD patients <22 years of age who received IVIS at our institution between 2009 and 2014. Anemia was defined as hemoglobin (Hgb) level below normal for age and gender and iron-deficiency anemia as serum iron studies and red cell mean corpuscular volume below normal ranges. Each IVIS infusion was evaluated for safety. Efficacy was defined as ≥2 g/dL increase in Hgb ≤12 weeks from IVIS initiation. Results. We identified 88 patients (Crohn’s disease, n = 52; ulcerative colitis, n = 33; IBD-unclassified, n = 3) who underwent 329 IVIS infusions over 121 courses. No patient developed anaphylaxis. Six patients developed minor adverse reactions. Of the 121 IVIS courses, 80 were included in the efficacy evaluation. There was a significant rise in Hgb (mean 9.1 ±1.4 to 11.9 ± 1.8 g/dL; P < .0001, paired t test). Overall, 58.7% (47/80 courses) resulted in goal Hgb increase. Conclusions. IVIS is safe and effective in treating iron-deficiency anemia in pediatric IBD. There were only minor adverse events, and the observed rise in Hgb was clinically significant, with the majority achieving goal Hgb.

Evaluation of Intravenous Iron Therapy Response to Manage Anemia in Pregnancy

Background: Iron deficiency anaemia is a common problem in antenatal patient especially in primigravida in developing world. The study was conducted to evaluate the efficacy of intravenous iron sucrose in antenatal primigravida anaemic cases.&#x0D; Aims and Objectives: The study was conducted to evaluate the response of intravenous iron therapy in anaemic antenatal primigravida patients. The rise of hemoglobin level was predicted after therapy.&#x0D; Materials and Methods: A prospective cross-sectional study was done in the antenatal clinic of Popular Medical College Hospital from January 2016 to December 2016. Primigravida women of e” 18 years with iron deficiency anaemia were included in this study. Pretreatment hemoglobin level was measured. After total dose of calculated iron, intravenous iron sucrose was infused to achieve the target hemoglobin. After completion of therapy hemoglobin was measured 2 weeks and 4 weeks after last dose of iron treatment. Mean, percentage, Chi-square test was done and P value &lt;0.05 was considered significant.&#x0D; Results: Among the 63 primigravida anaemic patients mean age of the study subjects were 23.98 years with mean gestational age were 23.54 weeks. Their pretreatment hemoglobin level was 5.42 gm/dl. After total dose infusion of iron sucrose, the mean rise of hemoglobin after 2 weeks was 8.87 gm/dl and after 4 weeks was 10.87 gm/dl respectively. This findings were statistically significant (P&lt;0.001). Attainment of target hemoglobin at the range of 9.1-11.0 gm/ dl was 50.79% and 65.08% after 2 weeks and 4 weeks respectively.&#x0D; Conclusion: Parenteral iron therapy in the form of iron sucrose proved to be better choice to correct iron deficiency anaemia in primigravida anaemic patients&#x0D; J Dhaka Medical College, Vol. 27, No.1, April, 2018, Page 79-82

Efficacy of Intravenous Iron Sucrose in Hemodialysis Patients with Restless Legs Syndrome (RLS): A Randomized, Placebo-Controlled Study.

BackgroundRestless legs syndrome (RLS) is a common disorder in hemodialysis (HD) patients that causes sleep disturbances and diminished quality of life. Because iron deficiency has been implicated in the pathogenesis of RLS, we sought to investigate the effects of intravenous (IV) iron sucrose on symptoms of RLS in HD patients.Material/MethodsThe study was a randomized, placebo-controlled study of 1000 mg iron sucrose versus normal saline as placebo. Patients were evaluated at baseline and 2 weeks after the last injection. The severity of RLS was assessed using the International RLS Study Group rating scale (IRLS). Blood samples were taken to measure iron parameters reflecting the iron status, including serum ferritin (SF) concentration, percentage transferrin saturation (TSAT%) and hemoglobin (Hb), and other biochemical parameters as safety assessments, including creatinine (Cr), urea, intact parathyroid hormone (iPTH), and the index of urea clearance (Kt/V). Adverse events were monitored in all subjects during the period of infusion.ResultsAfter 2 weeks, IRLS scores decreased more in the IV-iron group (−7.38±2.03) than in the placebo group (−0.81±2.61) (P=0.000). Serum ferritin, TSAT, and hemoglobin increased more in the IV-iron group (227.63±77.64 μg/L; 26.06±7.77%; 13.98±3.62g/L, respectively) than in the placebo group (SF, p=0.000; TSAT, p=0.000; Hb, p=0.000, respectively). There were no significant differences between IV-iron and placebo groups in Cr, urea, iPTH, and Kt/V. No adverse effects were observed in the study.ConclusionsIV iron sucrose is a safe and effective treatment for reducing RLS symptoms in HD patients over the short-term.

Evaluation of Efficacy of Intravenous Iron Sucrose in Management of Adolescent Iron Deficiency Anaemia

Evaluation of Efficacy of Intravenous Iron Sucrose in Management of Adolescent Iron Deficiency Anaemia

Response of Iron Deficiency Anemia to Intravenous Iron Sucrose in Pediatric Inflammatory Bowel Disease.

The objective of this retrospective study was to evaluate the safety and efficacy of intravenous iron sucrose (IS) in iron deficient children with inflammatory bowel disease (IBD) in remission. Electronic medical records at a university based pediatric children's hospital were searched for patients in age range 0 to 18 years with diagnosis of IBD and treatment with IS over a 1-year period. Response to IS treatment was assessed by posttreatment changes in ferritin, hemoglobin (Hb), and mean corpuscular volume (MCV). Patients with recorded symptoms of active disease were excluded from analysis of treatment response. Twelve patients were identified by the search criteria, 10 with Crohn's disease (CD), 2 with ulcerative colitis (UC). Data represent 8 patients in remission, 7 with CD and 1 with UC, who received a total of 34 IS infusions. Iron sucrose was administered in cycles of 2 infusions, 2.5 to 3.5 mg/kg/dose (maximum 200 mg), 1 week apart. Mean ferritin increased from 21.4 ± 9.2 to 52.9 ± 10.1 ng/mL (p = 0.0005), Hb from 10.9 ± 0.4 to 11.3 ± 0.3 g/dL (p = 0.02), and MCV from 76.9 ± 2 to 79.4 ± 2 fl (p = 0.006). Iron sucrose treatment normalized ferritin in 6 of 7, Hb in 2 of 8, and MCV in 2 of 5 patients with low pretreatment levels. No adverse effects were recorded. Two IS infusions of 2.5 to 3.5 mg/kg/dose (maximum 200 mg), given 1 week apart normalized ferritin levels in most pediatric IBD patients in remission without adverse effects. Further studies are needed to determine optimal dosing schedules.

Study of efficacy of intravenous iron sucrose in patients with moderate iron deficiency anemia in pregnancy

Introduction: Iron deficiency continues to be one of the most prevalent single nutrient deficiencies in the world. In the case of pregnant population, treatment of iron deficiency anemia efficiently would lead to a considerable reduction in the risk factors affecting maternal and fetal outcome. Materials and Methods: In this retrospective, case control study; the data of pregnant women who have received uniform dose of Intravenous and oral therapy for proven moderate iron deficiency anemia in the second trimester were studied for efficacy and safety parameters. The hemoglobin levels before and after initiating treatment in both groups were compared. Results and Conclusions: Intravenous and oral; both the treatments were associated with increment in hemoglobin but this rise was significantly more in the intravenous group than in oral. Comparing participants with low pretreatment hemoglobin among both groups, participants in the intravenous group were better benefited than oral due to respective treatment. Further it is found that hemoglobin increment is inversely proportional to the pretreatment hemoglobin irrespective of route of administration. Also intravenous iron is better tolerated compared to oral iron. So it can be concluded that intravenous iron therapy is much effective in correcting iron deficiency anemia in pregnancy than oral iron therapy.

Evaluation of effectiveness of intravenous iron sucrose in antenatal patients of iron deficiency anemia

Background: Iron deficiency anaemia (IDA) is the most common nutritional deficiency in pregnancy. Prophylactic oral iron is recommended during pregnancy to meet the increased requirement of iron. In India, more than 50% women become pregnant with low baseline haemoglobin level resulting in high incidence of moderate to severe anaemia in pregnancy where oral iron therapy cannot meet the requirement. This study was undertaken for critical evaluation of iron sucrose in terms of efficacy, safety, and feasibility along with any reduction in blood transfusion rate. Aims & Objective: To evaluate the efficacy of intravenous Iron sucrose in antenatal patients with Iron deficiency anaemia and to study the side effects of intra venous Iron sucrose. Material and Methods: This prospective study was conducted from Nov 2012 to June 2013 at VS General Hospital, Ahmedabad. 60 antenatal patients found to have anaemia having Hb level < 9 gm% were admitted and given intravenous iron sucrose therapy 100mg alternate day after calculating the dose of the iron requirement. Results: In patients having moderate anaemia (Hb 7-9 gm%), the rise in Hb found to be 2.17 ± 0.45 gm% from pre-treatment Hb of 7.88 ± 0.58 gm% to 9.9 ± 0.53 gm%. In patients with severe anaemia (Hb < 7 gm%), the rise in Hb was observed up to 2.73 ± 0.51 (SD) gm% after 1 month of iron sucrose treatment. No major side effects or anaphylactic reactions were noted during the study period. Conclusion: Parenterally administered iron sucrose elevates Hb and restores iron stores earlier and also that intravenous iron administration has led to the reduction in the rate of blood transfusion rate.

Treatment of childhood-onset restless legs syndrome and periodic limb movement disorder using intravenous iron sucrose

ObjectiveAn alternative treatment approach is needed for children who cannot tolerate oral iron preparations or when there is a need for rapid replenishment of iron stores. We report on the safety, adverse effects, and efficacy of intravenous iron sucrose in a retrospective sample of children with restless legs syndrome (RLS) or periodic limb movement disorder (PLMD). MethodsSixteen children with RLS/PLMD who received intravenous iron sucrose at our institution between 2005 and 2011 were identified. The diagnosis of RLS/PLMD was established after formal sleep consultation and nocturnal polysomnography (PSG). Serum ferritin was assayed in all 16 subjects prior to iron sucrose infusion and in 14 subjects after infusion. The medical records were reviewed for treatment-related details. ResultsThe mean age of subjects was 6.6years (range, 2–16y; 5/16 girls). The mean periodic limb movement index (PLMI) was 18.2±12.8. Fifteen of the 16 subjects (93.7%) had systemic or neurologic comorbidities. Fourteen of 16 (87.5%) subjects had received prior oral iron supplementation for sleep-related concerns, with the majority of the subjects either having gastrointestinal (GI) side effects or insufficient benefits. Intravenous iron sucrose therefore was provided to these 16 subjects through our outpatient pediatric infusion therapy center. The average dose of intravenous iron sucrose of 3.6mg/kg was infused over 2h. The baseline mean serum ferritin was 16.4±6.6ng/mL. After infusion with intravenous iron sucrose, the mean serum ferritin rose to 45.7±22.4ng/mL (n=14; [95% confidence interval, 17.2–41.3]; P<.0001). Parental assessment of response to iron sucrose therapy was conducted on follow-up clinic visits or via telephone calls. There was improved sleep in 62.5% (n=10) of subjects and no improvement in 12.5% (n=2) of subjects. No follow-up information was available for 25% (n=4) of subjects. Minor adverse events occurred in 25% (n=4) of subjects—two subjects experienced difficulty with peripheral intravenous catheter placement, while two had transient GI symptoms, such as anorexia, nausea, and vomiting. None of the subjects had anaphylaxis. ConclusionsIntravenous iron sucrose appears to be a relatively effective therapy for patients with childhood-onset RLS/PLMD and iron deficiency who do not tolerate or respond to oral iron supplements. Side effects were transient. The most common adverse events were difficulty with intravenous line placement and GI disturbance. There is a need for systematic prospective studies on the safety and efficacy of intravenous iron sucrose in RLS/PLMD in children.

Study of efficacy of intravenous iron sucrose therapy in iron deficiency anaemia of pregnancy

Background: Anaemia is the most common medical disorder in pregnancy and is responsible for higher of the maternal deaths in the developing countries. Objective: To determine the efficacy of intravenous iron sucrose, in anemic pregnant women, presenting at Mamata General Hospital, Khammam. Methods: Fifty patients with proved iron deficiency anemia having haemoglobin between 8-10gm% were included in the study. Total iron deficit was calculated by standard formula. Target haemoglobin to be achieved was 11gm%. Iron sucrose was administered by intravenous infusion in divided doses. Haemoglobin was repeated 3 weeks after the last dose of intravenous iron sucrose. Gestational Age, Socio economic class distribution was calculated in percentage , Pre and post treatment Hb% was calculated by mean and standard deviation and P-value was Assessed. Results: Majority of the patients i.e. 60% had gestational age between 32-34 weeks, 30% were in between 29-31 weeks of gestational age while 10% were between 26-28 weeks gestation. The Mean gestational age was 32.4±2.7. Distribution of cases by socio economic status showed, 40% belonged to lower class, 32% belonged to middle class and 28% were from upper class. Intravenous iron sucrose therapy was effective in 90% of the patients without any side effects. There were no allergic reactions. Conclusion: This study showed a significant improvement in the haemoglobin of the patients who received iron sucrose infusion. Patients achieved the target of 11 gram % haemoglobin. It was safe and well tolerated. Health Renaissance, January-April 2013; Vol. 11 No.1; 107-110 DOI: http://dx.doi.org/10.3126/hren.v11i2.8216

Is intravenous iron sucrose the treatment of choice for pregnant anemic women?

Anemia during pregnancy remains an important public health problem in developing countries like India. Anemia is the direct cause of 12-15% of maternal deaths. Iron deficiency is the commonest cause for anemia in the Indian subcontinent. Several preventive and therapeutic approaches are in practice. The available routes of iron supplementation are oral and intravenous. In spite of oral iron being least invasive, cheap and safe, the ineffectiveness of oral iron due to dietary inhibitors and poor compliance are well known. Intravenous iron sucrose can be a promising therapy for moderate to severely anemic pregnant women and has been in practice for quite some time in private and public health practices. In this article, we report the current evidence on the safety and efficacy of intravenous iron sucrose in anemic pregnant women on hematological and clinical outcomes. Though the evidence on its efficacy in improving hemoglobin and serum ferritin is convincing, its effect on maternal and fetal outcomes are unclear. This is primarily due to lack of well-designed and larger studies powered to detect difference in clinical outcomes. Hence, there is a need to gather evidence from a well-designed large randomized clinical trial conducted in a developing country. The results of such a study would feed into the national policy and would form the basis to frame guidelines for management of anemia in developing countries.

P43 A random prospective comparative study to evaluate the efficacy of intravenous iron sucrose versus oral ferrous sulphate in the treatment of iron deficiency anaemia of pregnancy

International Journal of Gynecology & ObstetricsVolume 107, Issue S2 p. S424-S424 Poster presentations P43 A random prospective comparative study to evaluate the efficacy of intravenous iron sucrose versus oral ferrous sulphate in the treatment of iron deficiency anaemia of pregnancy S. Pandit, S. PanditSearch for more papers by this authorP. Deshmukh, P. DeshmukhSearch for more papers by this author S. Pandit, S. PanditSearch for more papers by this authorP. Deshmukh, P. DeshmukhSearch for more papers by this author First published: 20 November 2009 https://doi.org/10.1016/S0020-7292(09)61535-6Citations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume107, IssueS2Abstracts of XIX FIGO World Congress of Gynecology and ObstetricsOctober 2009Pages S424-S424 RelatedInformation